MAIA · MAIA Biotechnology, Inc.

MAIA Biotechnology announced positive survival data from its Phase 2 THIO-101 trial, highlighting ateganosine sequenced with cemiplimab (Libtayo®) in advanced NSCLC patients who progressed after prior checkpoint inhibitor therapy. Eight patients across Parts A and B demonstrated overall survival exceeding two years without additional treatments, including one third-line patient reaching 33 months (versus an expected 5.8 months in this population) and four second-line patients surpassing 30 months (versus 10.5 months for standard chemotherapy or checkpoint inhibitors alone). All patients had failed previous CPI monotherapy, and most completed 29-34 cycles, with five still under follow-up. This data, presented via poster at the European Lung Cancer Congress on March 27, 2026, underscores ateganosine's telomere-targeting mechanism, which induces DNA damage, micronuclei formation, and immune activation via cGAS/STING and T-cell responses. CEO Vlad Vitoc noted the results as encouraging for the ongoing Phase 3 pivotal trial and THIO-101 Part C, which is enrolling up to 48 participants in Asia and Europe. The treatment has maintained an acceptable safety profile in 79 treated patients to date, positioning ateganosine as a potential breakthrough for second- or later-line NSCLC therapy in telomerase-positive tumors.